Section snippets

Metastatic hormone-sensitive prostate cancer (mHSPC)

The debate concerning the scientific accuracy and negative connotations of the word “castration” for patients has been discussed previously [3], [4] and is clearly a prominent example of the powers—positive and negative—mentioned above. In particular, we believe that the word “castration” is difficult for patients, partners, and families to hear and should be avoided when we describe this advanced prostate cancer disease state. mHSPC is the most common term for patients with newly diagnosed

Androgen deprivation–resistant prostate cancer (ARPC)

One widely used term is “castration-resistant” prostate cancer. Since all patients with this disease state are resistant to androgen deprivation, we propose a new term: androgen deprivation–resistant prostate cancer (ARPC).

Androgen receptor pathway inhibitors (ARPI)

The class of androgen receptor (AR) pathway inhibitors (eg, abiraterone acetate, apalutamide, darolutamide, enzalutamide) appears to have many names, going back decades to the first “anti-androgens” such as bicalutamide. Currently, various terms such as AR signaling inhibitors (ARSI), novel hormonal therapies (NHT), AR-targeted agents (ARTA), and second- or next-generation hormonal therapies are all used. Unfortunately, this nomenclature is not only confusing but is also prone to becoming

Combination therapy for mHSPC (ADT plus ARPI +/- docetaxel)

Multiple randomized trials have demonstrated superior overall survival in mHSPC with the addition of an ARPI to ADT (“doublet therapy”) or an ARPI to ADT and docetaxel chemotherapy (“triplet therapy”) [6], [7]. Describing regimens comprising two or three drugs as doublets or triplets may be descriptive but can easily be misinterpreted. For instance, the term “triplet therapy” in mHSPC has been used to describe ADT + ARPI + radiation therapy to the prostate by some investigators. Future

中文翻译：

---

名称中有什么？为什么文字在晚期前列腺癌中很重要

 部分片段

转移性激素敏感性前列腺癌 （mHSPC）

关于“阉割”一词对患者的科学准确性和负面含义的争论之前已经讨论过 [3]、[4]，这显然是上述力量（积极和消极）的一个突出例子。特别是，我们认为“阉割”这个词对于患者、伴侣和家人来说很难听到，当我们描述这种晚期前列腺癌疾病状态时应该避免使用。mHSPC 是新诊断

雄激素剥夺抵抗性前列腺癌 （ARPC）

一个广泛使用的术语是“去势抵抗性”前列腺癌。由于所有患有这种疾病状态的患者都对雄激素剥夺有抵抗力，因此我们提出了一个新术语：雄激素剥夺抵抗性前列腺癌 （ARPC）。

雄激素受体通路抑制剂 （ARPI）

雄激素受体 （AR） 通路抑制剂（如醋酸阿比特龙、阿帕鲁胺、达洛鲁胺、恩杂鲁胺）似乎有很多名称，可以追溯到几十年前第一个“抗雄激素”，如比卡鲁胺。目前，AR 信号抑制剂 （ARSI）、新型激素疗法 （NHT）、AR 靶向药物 （ARTA） 以及第二代或下一代激素疗法等各种术语都在使用。不幸的是，这种命名法不仅令人困惑，而且容易变得

mHSPC 的联合治疗（ADT 加 ARPI +/- 多西他赛）

多项随机试验表明，在 ADT 的基础上增加 ARPI（“双药疗法”）或在 ADT 和多西他赛化疗中加入 ARPI（“三联疗法”）[6]，[7]。将包含 2 种或 3 种药物的方案描述为双联或三联可能具有描述性，但很容易被误解。例如，mHSPC 中的术语“三联疗法”已被一些研究人员用于描述 ADT + ARPI + 前列腺放射疗法。前途